Research Analysts’ Weekly Ratings Changes for Alkermes (ALKS)

Several brokerages have updated their recommendations and price targets on shares of Alkermes (NASDAQ: ALKS) in the last few weeks:

• 8/7/2026 – Alkermes had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 7/30/2026 – Alkermes had its “neutral” rating reaffirmed by HC Wainwright.
• 7/29/2026 – Alkermes had its price target raised by JPMorgan Chase & Co. from $60.00 to $61.00. They now have a “neutral” rating on the stock.
• 7/29/2026 – Alkermes had its price target raised by Robert W. Baird from $48.00 to $58.00. They now have an “outperform” rating on the stock.
• 7/28/2026 – Alkermes had its “overweight” rating reaffirmed by Piper Sandler. They now have a $65.00 price target on the stock, up from $43.00.
• 7/20/2026 – Alkermes had its “buy” rating reaffirmed by Stifel Nicolaus. They now have a $63.00 price target on the stock, up from $45.00.
• 7/13/2026 – Alkermes had its price target raised by Needham & Company LLC from $61.00 to $62.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Alkermes is now covered by JPMorgan Chase & Co.. They set a “neutral” rating and a $60.00 price target on the stock.
• 7/2/2026 – Alkermes had its price target raised by Mizuho from $53.00 to $65.00. They now have an “outperform” rating on the stock.
• 6/29/2026 – Alkermes had its price target raised by Wells Fargo & Company from $44.00 to $65.00. They now have an “overweight” rating on the stock.
• 6/29/2026 – Alkermes had its “underperform” rating reaffirmed by Bank of America Corporation.
• 6/24/2026 – Alkermes had its price target raised by Needham & Company LLC from $54.00 to $61.00. They now have a “buy” rating on the stock.
• 6/22/2026 – Alkermes had its price target raised by TD Cowen from $42.00 to $50.00. They now have a “buy” rating on the stock.
• 6/18/2026 – Alkermes had its “neutral” rating reaffirmed by HC Wainwright.
• 6/18/2026 – Alkermes had its price target raised by Needham & Company LLC from $50.00 to $54.00. They now have a “buy” rating on the stock.

Insider Activity

In related news, EVP Craig C. Hopkinson sold 9,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $51.51, for a total value of $463,590.00. Following the transaction, the executive vice president owned 73,389 shares in the company, valued at $3,780,267.39. The trade was a 10.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy Lynn Md Snyderman sold 44,472 shares of the stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $50.35, for a total value of $2,239,165.20. Following the sale, the director owned 15,395 shares of the company’s stock, valued at approximately $775,138.25. The trade was a 74.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 79,574 shares of company stock worth $3,901,478 in the last three months. Corporate insiders own 4.59% of the company’s stock.

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.